Actively Recruiting
Utility of PET-MRI in Post-treatment Surveillance of Paediatric Brain Tumours: a Pilot Study
Led by Sheffield Children's NHS Foundation Trust · Updated on 2026-05-06
5
Participants Needed
1
Research Sites
26 weeks
Total Duration
On this page
Sponsors
S
Sheffield Children's NHS Foundation Trust
Lead Sponsor
G
GE Healthcare
Collaborating Sponsor
AI-Summary
What this Trial Is About
Researchers are exploring the use of PET-MRI for monitoring children treated for high-grade gliomas or medulloblastomas, which are malignant brain tumors common in pediatric patients. These tumors are challenging to manage due to difficulties distinguishing tumor recurrence from treatment-related changes using conventional MRI alone. The study aims to improve diagnostic accuracy and clinical management during post-treatment surveillance, particularly important for evaluating new therapies in early clinical trials. Participants will undergo PET-MRI scans that combine MRI's detailed images with PET scans using the tracer 18F-fluodeoxyglucose (18F-FDG) to detect metabolic activity associated with tumor cells. This imaging method may better differentiate between tumor recurrence and post-treatment changes compared to traditional MRI or PET/CT scans. The study will assess the feasibility and impact of PET-MRI in diagnosing these brain tumors after treatment over a year. During the study, children will have PET-MRI scans and will be evaluated for their ability to complete the scan without general anesthesia. Researchers will measure how many patients can be recruited within one year, assess the acceptability of the procedure, and evaluate its accuracy. The study will monitor participants for at least one year to gather data on the effectiveness of PET-MRI in post-treatment surveillance.
CONDITIONS
Brief Title
Utility of PET-MRI in Surveillance of Paediatric Brain Tumours
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Have a presumptive or histologically confirmed diagnosis of a malignant brain tumour requiring treatment
- Diagnostic uncertainty about tumour recurrence post-treatment based on conventional MR imaging in the opinion of the MDT
- Have a life expectancy of at least three months
- Able to comply with an MRI scan without a general anaesthetic
You will not qualify if you...
- Unable to comply with an MRI scan without a general anaesthetic
- Diabetes or other causes of hyperglycaemia
- Pregnancy
- Patient body habitus above scanner dimensions
- Standard contra-indication to MRI (eg. pacemaker, non-compatible metallic implants, altered renal function)
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Up to 1 year
Participants undergo PET-MRI scans using the tracer 18F-FDG to monitor for tumour recurrence or progression after initial treatment.
1 or more PET-MRI visits as recommended by the clinical team
Trial Site Locations
Total: 1 location
1
Sheffield Children's Hospital
Sheffield, South Yorkshire, United Kingdom, S10 1SN
Actively Recruiting
Research Team
D
David King, MBChB
K
Keith Pugh, PhD
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
OTHER
Number of Arms
1
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here